Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA authorizes abortion drug distribution by mail

By Brian Buntz | December 17, 2021

FDA logoThe FDA has decided to allow dispensing of mifepristone from Danco Laboratories by mail using certified prescribers of pharmacies. The move also allows dispensing of the drug via telemedicine.

The agency had previously required that individuals obtain the abortion drug mifepristone (Mifeprex) in person.

FDA notes that the mail-order distribution model became popular during the pandemic, leading the agency to cease enforcing the in-person dispensing rule.

Some states, however, have moved to block the distribution of the drug, which is also known as RU486.

FDA indicates that the progestin antagonist mifepristone be used together with the drug misoprostol in the first 70 days of gestation. Misoprostol is a widely available prescription drug indicated as an ulcer treatment. FDA recommends that patients take mifepristone first and then misoprostol two days later.

Nearly half of U.S. states have either banned or limited the use of the mifepristone-misoprostol cocktail.

Demand for abortion pills has jumped recently as the Supreme Court considers the future of Roe v. Wade, according to Bloomberg Law.

Comments

  1. JAnice says

    May 5, 2022 at 10:12 am

    Hello I need advice, Im 4 months pregnant when I took mifepristone 200 mg on 28th April but I didnt take the second pill which is the misprostol because I want to pursue my pregnancy. I cant sleep im bothered until now, does mife 200 mg can cause birth defects or any problems when I born my baby?
    Please help, thankyou!

    Reply
    • Brian Buntz says

      May 5, 2022 at 4:39 pm

      Hi Janice,

      This UK site found there are “insufficient data to determine if mifepristone exposure in monotherapy is associated with an increased risk of congenital malformation in the fetus.”

      It also concluded that “additional fetal monitoring may be warranted for ongoing pregnancies” just to be sure.

      A 2013 study concluded that the data were “reassuring” for continuation of pregnancy after mifepristone exposure.

      Please follow up with a physician.

      Best wishes,
      Brian

      Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors
Pfizer logo
Pfizer recalls certain lots of blood-pressure drug Accupril
CMS Centers for Medicare & Medicaid Services
CMS will limit coverage of Aduhelm to people in clinical trials

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards